Efficiency of low dosage apatinib in post-first-line treatment of advanced lung adenocarcinoma

Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients without driver mutation. However, few drugs could be selected when diseases progressed after second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), apatinib wa...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Da-Xiong, Wang, Chang-Guo, Lei, Wei, Huang, Jian-An, Jiang, Jun-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630408/
https://www.ncbi.nlm.nih.gov/pubmed/29029508
http://dx.doi.org/10.18632/oncotarget.19908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630408/
https://www.ncbi.nlm.nih.gov/pubmed/29029508
http://dx.doi.org/10.18632/oncotarget.19908

Ejemplares similares